RecruitingNot ApplicableNCT05243290

Nicotinamide Riboside Clinical Trial for GWI

A Randomized Double-blind Placebo-controlled Clinical Trial of Nicotinamide Riboside for Restoring Mitochondrial Bioenergetics in Gulf War Illness

Sponsor

Roskamp Institute Inc.

Enrollment

52 participants

Start Date

Apr 13, 2022

Study Type

INTERVENTIONAL

Conditions

Gulf War Illness

Summary

In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

Eligibility

Min Age: 47 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Nicotinamide Riboside and Placebo for people with gulf war illness. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 47 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTNicotinamide Riboside

The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.

DIETARY_SUPPLEMENTPlacebo

Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.